Orthorexia Nervosa in Fibromyalgia
ConditionFibromyalgia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-65
SponsorBeylikduzu State Hospital
About this trial
This clinical cross-sectional study will include 84 female patients aged between 18 and 65 years who have been diagnosed with fibromyalgia syndrome according to the 2010 American College of Rheumatology diagnostic criteria. Sociodemographic data will be recorded at the beginning of the study. Pain severity will be assessed using the Visual Analog Scale (VAS). Orthorexia nervosa-related symptoms will be evaluated with the ORTO-11 scale. Body image will be assessed with the Body Appreciation Scale 2, mood will be evaluated using the Hospital Anxiety and Depression Scale (HADS), and fibromyalgia-related impact will be assessed with the Fibromyalgia Impact Questionnaire (FIQ).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Female patients aged 18-65 years.
Diagnosis of fibromyalgia syndrome according to the 2010 American College of Rheumatology diagnostic criteria.
Willingness to participate and provision of written informed consent.
Disqualifiers
Refusal to participate.
Presence of diagnosed psychiatric disorders.
Presence of cognitive impairment.
Use of medications that may affect mood.
Trial population
Patients with fibromyalgia syndrome
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
Fibromyalgia
Other interventionno intervention
Treatment groups
84 Participants
are divided into 1 treatment groupGroup A: fibromyalgia group1 intervention
Trial outcomes
Primary outcomes
1
ORTO-11 Scale
The ORTO-11 assesses orthorexic tendencies, which refer to an unhealthy obsession with healthy eating. It consists of 11 items rated on a 4-point Likert scale. Total scores range from 11 to 44, with lower scores indicating a higher risk of orthorexia nervosa.
Time frame
BaselineSecondary outcomes
1
Hospital Anxiety Scale (HADS-A):
The HADS-A subscale evaluates symptoms of anxiety. It consists of 7 items, each scored between 0 and 3. The total score ranges from 0 to 21, with higher scores indicating higher levels of anxiety.
Time frame
Baseline2
Hospital Depression Scale (HADS-D):
The HADS-D subscale evaluates symptoms of depression. It consists of 7 items, each scored between 0 and 3. The total score ranges from 0 to 21, with higher scores indicating higher levels of depression.
Time frame
Baseline3
Body Appreciation Scale-2 (BAS-2)
The BAS-2 assesses positive body image and appreciation of one's body. It consists of 10 items rated on a 5-point Likert scale (1 = Never, 5 = Always). Total scores range from 10 to 50, with higher scores indicating greater body appreciation.
Time frame
Baseline4
Fibromyalgia Impact Questionnaire (FIQ)
The FIQ is a self-reported instrument designed to assess the health status and functional impact of fibromyalgia. It consists of 10 items evaluating physical functioning, work status, depression, anxiety, sleep, pain, stiffness, fatigue, and well-being. The total score ranges from 0 to 100, with higher scores indicating greater functional impairment and symptom severity.
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov